Latest Articles
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
Woman's ingenious song is a call for science to actually study the dynamics of female body - Upworthy
Woman's ingenious song is a call for science to actually study the dynamics of female body Upworthy
Published: June 21, 2024, 7 a.m.
The evolving roles of extracellular vesicles in embryo-maternal communication - Nature.com
The evolving roles of extracellular vesicles in embryo-maternal communication Nature.com
Published: June 21, 2024, 7 a.m.
The Supreme Court Overruled Roe Two Years Ago, Ending Right To Abortion. Birth Control May Be Next - Forbes
The Supreme Court Overruled Roe Two Years Ago, Ending Right To Abortion. Birth Control May Be Next Forbes
Published: June 21, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer - Medpage Today
Two New Immunotherapy-Chemo Options Approved for Endometrial Cancer Medpage Today
Published: June 18, 2024, 7 a.m.
Link copied to clipboard!